Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiota-dependent transcriptional priming of lung innate immune cells in a mouse model of LPS-induced sepsis-associated lung injury.

Journal of oral biosciences·2026
Same author

Detection rate and maximum diameter of thyroid cysts among children and adolescents in thyroid ultrasound examination, The Fukushima Health Management Survey.

Endocrine journal·2026
Same author

Clinical and Mucosal Transcriptomic Profiling of Adult Food Protein-Induced Enterocolitis Syndrome.

Allergy·2026
Same author

Integration of the Tokyo 2020 Terminology Into the "New World" Terminology.

Journal of hepato-biliary-pancreatic sciences·2025
Same author

Laparoscopic versus open liver resection in patients aged at least 80 years: retrospective propensity score-matched cohort study.

BJS open·2025
Same author

Anatomy on the Border Expert Consensus Meeting: Current Status and Future Perspectives of Three-Dimensional Image Reconstruction and Immersive Technologies in Liver Surgery.

Asian journal of endoscopic surgery·2025
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Anticancer efficacy with cisplatin delivery systems].

Akio Sugitachi1, Yusuke Kimura, Tetsuya Itabashi

  • 1Dept. of Surgery, Iwate Medical University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 13, 2011
PubMed
Summary
This summary is machine-generated.

New cisplatin delivery systems using deacetylated chitin (DAC-70) showed significant anticancer efficacy in mice. These novel systems improved survival rates compared to conventional cisplatin, offering promising results for cancer treatment.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Experiment Videos

Last Updated: Jun 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Area of Science:

  • Biomaterials Science
  • Oncology
  • Drug Delivery Systems

Background:

  • Cisplatin (CDDP) is a widely used chemotherapy drug.
  • Developing effective drug delivery systems is crucial for improving cancer treatment outcomes.
  • Deacetylated chitin (DAC-70) shows potential as a biocompatible drug carrier.

Purpose of the Study:

  • To develop and evaluate novel cisplatin (CDDP) delivery systems using deacetylated chitin (DAC-70).
  • To assess the in vivo anticancer efficacy of these novel systems in a mouse cancer model.

Main Methods:

  • Two cisplatin delivery systems (System A and System B) were formulated using DAC-70.
  • Cancer-bearing mice were established by intraperitoneal inoculation of MM-46 cancer cells.
  • Mice were treated with System A, System B, conventional CDDP, or left untreated.
  • Anticancer efficacy was evaluated by monitoring survival rates and recurrence of ascites.

Main Results:

  • Both DAC-70 based systems exhibited a sol-to-gel transition at body temperature (37°C).
  • Four-week survival rates were 60% for System A, 90.9% for System B, 33.3% for conventional CDDP, and 0% for the control group.
  • No ascites recurrence was observed in long-term survivors treated with Systems A and B.

Conclusions:

  • The novel DAC-70 and CDDP delivery systems demonstrated significant antitumor efficacy in vivo.
  • These systems offer a promising alternative to conventional cisplatin administration.
  • Further research will focus on developing a clinically applicable conjugated system of DAC-70 and CDDP.